The efficacy of neutralizing monoclonal antibodies in transplant recipients with mild-to-moderate COVID-19

INTRODUCTION: Transplant recipients (TRs) are at high risk for severe coronavirus disease 2019 (COVID-19). Neutralizing monoclonal antibodies (mAbs) are used for treating mild-to-moderate COVID-19. However, reports comparing the efficacy of COVID-19 treatment without/with mAbs in TRs are limited. We...

Descripción completa

Detalles Bibliográficos
Autores principales: Arimura, Ken, Tagaya, Etsuko, Kikuchi, Ken, Mitsuda, Toshihiro, Ebihara, Fumiya, Maruyama, Takumi, Hamada, Yukihiro, Unagami, Kohei, Kanzawa, Taichi, Sekiguchi, Haruki, Shimamoto, Ken, Ishida, Hideki, Egawa, Hiroto, Tanaka, Junji, Kawana, Masatoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier B.V. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796351/
https://www.ncbi.nlm.nih.gov/pubmed/36584927
http://dx.doi.org/10.1016/j.trim.2022.101777

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796351/
https://www.ncbi.nlm.nih.gov/pubmed/36584927
http://dx.doi.org/10.1016/j.trim.2022.101777

Ejemplares similares